Financials data is unavailable for this security.
View more
Year on year Emmaus Life Sciences Inc grew revenues 60.94% from 18.39m to 29.60m while net income improved from a loss of 10.63m to a smaller loss of 3.73m.
Gross margin | 95.48% |
---|---|
Net profit margin | -26.32% |
Operating margin | -2.84% |
Return on assets | -13.79% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, Emmaus Life Sciences Inc increased its cash reserves by 26.03%, or 526.00k. Cash Flow from Financing totalled 2.48m or 8.37% of revenues. In addition the company used 1.50m for operations while cash used for investing totalled 432.00k.
Cash flow per share | -0.0656 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.8927 |
---|---|
Tangible book value per share | -0.8927 |
More ▼
Balance sheet in USDView more
Current ratio | 0.1408 |
---|---|
Quick ratio | 0.1153 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼